Corteva
CTVA
$80.53
-1.23%
Corteva, Inc. is a pure-play agricultural inputs company formed in 2019 from the spin-off of DowDuPont's agriculture division, operating globally across two core segments: seeds (including the flagship Pioneer brand) and crop protection chemicals such as herbicides, fungicides, and insecticides. The company is a market leader in seed genetics and crop protection, with roughly half of its revenue generated in North America and a significant presence in Latin America and Europe. The dominant investor narrative centers on Corteva's planned spin-off of its seeds business into a separate entity named Vylor in late 2026, leaving the remaining Corteva as a pure-play crop protection company. This strategic separation, combined with a strong Q1 2026 earnings beat (revenue up 11% year-over-year), has driven renewed interest, though the stock remains sensitive to agricultural commodity cycles and farmer input spending. Recent analyst actions have been largely constructive, with firms like Mizuho and Barclays maintaining Outperform/Overweight ratings, reflecting confidence in the company's portfolio and margin trajectory.…
CTVA
Corteva
$80.53
Investment Opinion: Should I buy CTVA Today?
Corteva is rated a Buy based on a synthesis of its earnings recovery, strong balance sheet, and the potential value unlock from the Vylor spin-off. The analyst consensus is Buy with a mean rating of 1.86, and the average target price of $92.10 implies 9.8% upside from the current $83.90. The core thesis is that Corteva is in the early stages of an earnings rebound, with Q1 2026 EPS of $1.07 up from $0.95 a year ago, and the spin-off could act as a catalyst for multiple expansion.
The supporting evidence is compelling: revenue grew 11.05% YoY in Q1 2026, gross margin improved to 48.5% from 46.98%, and operating margin expanded to 23.67% from 18.72%. The forward PE of 20.39x is in line with the sector average of 18-22x, while the PEG ratio of 1.89x is reasonable given expected EPS growth to $5.16. Free cash flow of $2.046B and a low debt-to-equity of 0.107 provide financial flexibility. The dividend yield of 1.04% with a payout ratio of 43.4% is sustainable and offers modest income.
Key risks include the seasonal earnings volatility, with Q4 2025 posting a $552M net loss, and the premium EV/EBITDA of 14.21x versus the sector median of 12x. The spin-off execution risk is significant; delays or unfavorable terms could derail the value-unlock thesis. The rating would upgrade to Strong Buy if the forward PE compresses below 18x or if revenue growth accelerates above 15%. It would downgrade to Hold if revenue growth decelerates below 8% or if the spin-off is postponed. Relative to its history and peers, the stock appears fairly valued, with the market pricing in a successful spin-off and continued earnings recovery.
Sign up to view all
CTVA 12-Month Price Forecast
Corteva presents a compelling medium-term investment case driven by an earnings recovery, a strong balance sheet, and the potential value unlock from the Vylor spin-off. The Q1 2026 revenue growth of 11.05% and EPS of $1.07 demonstrate accelerating momentum, while the forward PE of 20.39x is reasonable relative to the sector. The analyst consensus is bullish, with a $92.10 average target implying 9.8% upside. However, the stock's low beta of 0.577 and seasonal earnings volatility warrant a medium confidence rating. I would upgrade to high confidence if the spin-off is confirmed on favorable terms and revenue growth exceeds 12% for two consecutive quarters. I would downgrade to neutral if revenue growth decelerates below 8% or if the spin-off is delayed beyond 2026.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $92.60 and implied upside of +15.0% versus the current price.
Average Target
$92.60
0 analysts
Implied Upside
+15.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$78 - $103
Analyst target range
Corteva is covered by 20 analysts, with a consensus recommendation of "Buy" (mean rating of 1.86 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average price target is $92.10, which implies approximately 9.8% upside from the current price of $83.90. The consensus is bullish, with the majority of analysts rating the stock a Buy or Outperform. Recent institutional ratings show a mix of Outperform and Overweight ratings from firms like Mizuho, Barclays, Morgan Stanley, and RBC Capital, while UBS and Citigroup maintain Neutral ratings, indicating some caution but overall positive sentiment.
The target price range spans from a low of $78.00 to a high of $103.00, a spread of $25.00 or about 32% of the current price. The high target of $103.00 implies roughly 22.8% upside and likely assumes successful execution of the seeds spin-off, multiple expansion, and accelerating earnings growth. The low target of $78.00 represents about 7% downside and may price in risks such as margin compression, adverse weather affecting agricultural demand, or a delayed or unfavorable spin-off outcome. The wide spread suggests moderate uncertainty among analysts, but the concentration of ratings in the Buy/Outperform category signals stronger conviction on the upside. The estimated EPS average of $5.16 for the next fiscal year, with a range of $5.05 to $5.29, supports the consensus view of a significant earnings rebound.
Drowning in data?
Find the real signal!
Bulls vs Bears: CTVA Investment Factors
The bull case for Corteva rests on a clear earnings recovery, a fortress balance sheet, and the potential value unlock from the Vylor spin-off. Q1 2026 revenue growth of 11.05% and EPS of $1.07 demonstrate accelerating momentum, while the forward PE of 20.39x and analyst target of $92.10 offer a favorable risk/reward. However, the bear case highlights seasonal earnings volatility, a premium EV/EBITDA multiple, and low returns on capital that could limit upside. The most important tension is whether the spin-off will successfully unlock value or introduce operational distractions and costs. Given the strong Q1 beat and analyst consensus, the bull case currently has stronger evidence, but the stock's low beta and commodity sensitivity warrant caution.
Bullish
- Earnings recovery underway: Q1 2026 revenue grew 11.05% YoY to $4.905B, with net income of $720M and EPS of $1.07, up from $0.95 in Q1 2025. This marks a clear acceleration from the 5.6% YoY growth in Q2 2025, signaling that the company is gaining momentum after a soft 2024.
- Strong balance sheet and cash flow: Debt-to-equity is just 0.107, well below industry averages, and trailing twelve-month free cash flow is $2.046B. The current ratio of 1.43 provides ample liquidity, and the low leverage gives Corteva flexibility to fund its planned spin-off without financial strain.
- Attractive forward valuation: The forward PE of 20.39x is in line with the agricultural inputs sector average of 18-22x, while the trailing PE of 41.89x reflects depressed trailing earnings. The PEG ratio of 1.89x is reasonable given expected EPS growth to $5.16 next year, implying a 20%+ earnings CAGR.
- Analyst consensus bullish: 20 analysts rate CTVA a Buy with a mean rating of 1.86 (1=Strong Buy), and the average price target of $92.10 implies 9.8% upside. The high target of $103.00 suggests 22.8% upside if the spin-off executes well.
Bearish
- Seasonal earnings volatility: Corteva reported net losses of $552M in Q4 2025 and $320M in Q3 2025, highlighting the highly seasonal nature of the agricultural business. This volatility makes trailing metrics unreliable and can lead to sharp stock price swings around earnings.
- Premium EV/EBITDA multiple: The EV/EBITDA of 14.21x is above the sector median of around 12x, leaving little room for error. If earnings recovery stalls or the spin-off is delayed, multiple compression could pressure the stock.
- Low beta limits upside: With a beta of 0.577, CTVA is roughly 42% less volatile than the S&P 500. While this reduces downside risk, it also means the stock may lag in strong bull markets, as evidenced by its 1-year relative strength of -1.27% versus SPY.
- Modest returns on capital: ROE of 4.53% and ROA of 4.55% are low, reflecting the capital-intensive nature of the business. Improving these metrics is crucial to justify the forward PE of 20.39x and support long-term value creation.
CTVA Technical Analysis
Corteva's stock is in a sustained uptrend, with a 1-year price change of +14.95% and a year-to-date gain of +23.82%. The current price of $83.90 sits at approximately 77% of its 52-week range (low of $60.54, high of $90.97), indicating the stock is in the upper half of its annual range but not at its peak. This positioning suggests healthy momentum without extreme overextension, leaving room for further upside if the broader uptrend persists. The 52-week high of $90.97 was set in late July 2026, and the stock has since pulled back modestly, trading about 7.8% below that peak.
Short-term momentum has been positive but decelerating. The 1-month price change is +11.08%, significantly outpacing the 3-month change of +10.19% and the 6-month change of +5.92%, indicating that recent gains have accelerated. However, the stock has slipped from its September 2 high of $89.97 to $83.90, a decline of roughly 6.7% in just over a week, suggesting a near-term pullback. Relative strength versus the S&P 500 is strong over the 1-month (+12.14%) and 3-month (+7.15%) periods, but negative over the 6-month (-9.48%) and 1-year (-1.27%) periods, highlighting that Corteva has outperformed recently but lagged over longer horizons. The 1-month relative strength of +12.14% versus SPY's -1.06% is particularly notable, showing Corteva's recent decoupling from a weak broad market.
Key technical levels are defined by the 52-week low of $60.54 as major support and the 52-week high of $90.97 as resistance. A breakout above $90.97 would signal a new leg higher and likely attract momentum buyers, while a breakdown below $60.54 would indicate a significant trend reversal. The stock's beta of 0.577 is notably low, meaning it is roughly 42% less volatile than the S&P 500, which is attractive for risk-averse investors but may limit upside capture in strong bull markets. The maximum drawdown over the past year was -18.7%, reflecting moderate risk, and the current price is about 38.6% above the 52-week low, underscoring the recovery from earlier lows.
Beta
0.58
0.58x market volatility
Max Drawdown
-18.7%
Largest decline past year
52-Week Range
$61-$91
Price range past year
Annual Return
+14.0%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | +2.5% | -1.0% |
| 3m | +2.5% | +2.0% |
| 6m | +4.1% | +17.4% |
| 1y | +14.0% | +15.0% |
| ytd | +18.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Corteva's revenue trajectory is showing a clear rebound. In Q1 2026, revenue reached $4.905 billion, up 11.05% year-over-year from $4.417 billion in Q1 2025. This follows a strong Q2 2025 where revenue was $6.456 billion, up from $6.112 billion in Q2 2024, and a Q4 2025 revenue of $3.91 billion versus $3.978 billion in Q4 2024. The multi-quarter trend indicates growth is accelerating, driven by both seed and crop protection segments. Segment data shows seeds generated $3.023 billion and crop protection $1.882 billion in the most recent period, with herbicides ($1.027 billion) and insecticides ($377 million) being the largest crop protection categories. The 11% YoY growth in Q1 2026, following a 5.6% YoY increase in Q2 2025, suggests the company is gaining momentum after a soft 2024.
Profitability has been volatile but is improving. In Q1 2026, net income was $720 million with a net margin of 14.68% and a gross margin of 48.5%. This compares favorably to Q1 2025's net income of $652 million and gross margin of 46.98%. However, the company reported a net loss of $552 million in Q4 2025 (net margin -14.12%) and a loss of $320 million in Q3 2025, reflecting the seasonal nature of the agricultural business. The trailing twelve-month net margin is 6.29%, while the operating margin stands at 15.05% and gross margin at 47.29%. The Q1 2026 operating margin of 23.67% is a strong improvement from 18.72% in Q1 2025, indicating better cost control and pricing power. Compared to the agricultural inputs industry, where gross margins typically range from 30-50%, Corteva's 47.3% gross margin is at the higher end, reflecting its premium seed genetics and branded crop protection products.
Corteva's balance sheet is conservatively managed with a debt-to-equity ratio of just 0.107, well below the industry average, and a current ratio of 1.43, indicating adequate liquidity. The company generated $2.046 billion in trailing twelve-month free cash flow, though Q1 2026 free cash flow was negative $2.972 billion due to seasonal working capital outflows (a typical pattern for agricultural companies ahead of the planting season). Return on equity is 4.53%, and return on assets is 4.55%, which are modest but reflect the capital-intensive nature of the business. The dividend yield is 1.04% with a payout ratio of 43.4%, leaving ample room for reinvestment. The low debt-to-equity ratio and consistent free cash flow generation (positive in Q4 2025 at $4.153 billion and Q2 2025 at $829 million) suggest the company can fund its spin-off and growth initiatives internally without straining its financial position.
Quarterly Revenue
$4.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
48.5%
Latest Quarter
Free Cash Flow
$2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Because Corteva reported positive trailing net income (EPS of $0.024), the PE ratio is the primary valuation metric. The trailing PE is 41.89x, while the forward PE is 20.39x, implying the market expects earnings to more than double in the coming year. This large gap reflects the market's confidence in a significant earnings recovery, likely driven by the upcoming seeds spin-off, margin expansion, and normalized agricultural demand. The forward PE of 20.39x is more reasonable and aligns with the company's estimated EPS of $5.16 for the next fiscal year.
Compared to the agricultural inputs industry, Corteva's forward PE of 20.39x is roughly in line with or slightly below the sector average, which typically ranges from 18x to 22x for large-cap ag companies. The price-to-sales ratio of 2.62x and price-to-book ratio of 1.89x are also moderate, suggesting the stock is not richly valued relative to its revenue and book value. The EV/EBITDA of 14.21x is slightly above the sector median of around 12x, but justified by Corteva's strong brand portfolio, leading market position, and the potential value unlock from the spin-off. The PEG ratio of 1.89x indicates the stock is trading at a premium to its growth rate, but this may be overstated given the expected earnings acceleration.
Historically, Corteva's PE ratio has been highly volatile due to seasonal losses and one-time items, ranging from negative values to over 50x. The current trailing PE of 41.89x is elevated compared to the 2025 Q2 PE of 9.65x and the 2024 Q2 PE of 8.79x, but those periods benefited from unusually strong quarterly earnings. The forward PE of 20.39x is more consistent with the company's historical average of around 18-22x during normal earnings periods. The price-to-book ratio of 1.89x is near the middle of its historical range (1.35x to 2.31x over the past three years), suggesting the stock is neither cheap nor expensive on an asset basis. Overall, the valuation appears fair, with the market pricing in a successful execution of the spin-off and continued earnings recovery.
PE
41.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Corteva's financial risks are moderate but notable. The company carries a low debt-to-equity ratio of 0.107 and a current ratio of 1.43, indicating a healthy balance sheet. However, seasonal working capital swings are significant: Q1 2026 free cash flow was negative $2.972B, a typical pattern ahead of the planting season, which could strain liquidity if not managed. Additionally, trailing net margin is only 6.29%, and ROE is 4.53%, reflecting thin profitability relative to the capital employed. The company's earnings are highly seasonal, with Q4 2025 posting a net loss of $552M, which introduces volatility and makes quarterly comparisons challenging.
Market and competitive risks include valuation compression if the spin-off disappoints or if agricultural commodity prices decline. The EV/EBITDA of 14.21x is above the sector median of 12x, leaving room for multiple contraction. With a beta of 0.577, the stock is less sensitive to broad market moves, but it remains exposed to sector-specific headwinds such as regulatory changes on crop protection chemicals or shifts in farmer planting decisions. The low relative strength over the 6-month (-9.48%) and 1-year (-1.27%) periods suggests the stock has lagged the broader market, and a rotation out of defensive names could further pressure the shares. Recent news is absent, but any negative regulatory or weather-related events could trigger a sell-off.
In a worst-case scenario, a combination of a failed spin-off, a sharp decline in agricultural commodity prices, and margin compression could drive the stock down to its 52-week low of $60.54, representing a 27.8% decline from the current price of $83.90. The analyst low target of $78.00 implies a more modest 7% downside, but if earnings disappoint and the forward PE compresses to 15x on lower EPS estimates, the stock could fall below $70. The maximum drawdown over the past year was -18.7%, and a similar drawdown from the current price would take the stock to around $68.20. Investors could lose 20-30% in a severe adverse scenario, underscoring the importance of monitoring the spin-off execution and commodity trends.
FAQ
The most severe risk is the seasonal earnings volatility, with Q4 2025 posting a net loss of $552M, which can cause sharp stock price swings. Second, the spin-off execution risk is significant; a delay or unfavorable terms could derail the value-unlock thesis and lead to multiple compression. Third, commodity price sensitivity is a major external risk, as a decline in corn or soybean prices could reduce farmer input spending and pressure revenue. Fourth, the premium EV/EBITDA of 14.21x versus the sector median of 12x leaves little margin for error, and any earnings miss could trigger a de-rating. Finally, the low beta of 0.577 means the stock may underperform in strong bull markets, as seen in its 1-year relative strength of -1.27%.
Our 12-month forecast for CTVA includes a base case (55% probability) with a target range of $88-95, assuming the spin-off proceeds on schedule and EPS meets the $5.16 consensus. The bull case (25% probability) targets $95-103, driven by a successful spin-off, revenue growth above 12%, and multiple expansion. The bear case (20% probability) targets $60-78, assuming a delayed spin-off, commodity price declines, and margin compression. The most likely scenario is the base case, with the key assumption being that Corteva executes its strategic separation without major disruptions and maintains its earnings recovery trajectory.
CTVA appears fairly valued. The forward PE of 20.39x is in line with the agricultural inputs sector average of 18-22x, while the trailing PE of 41.89x is elevated due to depressed trailing earnings. The price-to-sales ratio of 2.62x and price-to-book ratio of 1.89x are moderate, and the EV/EBITDA of 14.21x is slightly above the sector median of 12x. The PEG ratio of 1.89x suggests a premium to growth, but this may be overstated given the expected earnings acceleration to $5.16 per share. The market is pricing in a successful spin-off and continued earnings recovery, leaving little room for disappointment.
From a risk/reward perspective, CTVA offers a favorable setup with 9.8% upside to the average analyst target of $92.10 and a high target of $103.00 implying 22.8% upside. The forward PE of 20.39x is reasonable, and the company's low debt-to-equity of 0.107 and $2.046B free cash flow provide a margin of safety. However, the biggest downside risk is a failed or delayed spin-off, which could send the stock to the $78 low target or even the 52-week low of $60.54. For long-term investors comfortable with agricultural cyclicality, CTVA is a good buy at current levels, but short-term traders should be cautious given the seasonal earnings volatility and the stock's low beta.
CTVA is best suited for long-term investment, with a suggested minimum holding period of 2-3 years to fully capture the value unlock from the Vylor spin-off and the earnings recovery cycle. The stock's low beta of 0.577 and seasonal earnings volatility make it less ideal for short-term trading, as quarterly results can be unpredictable. The dividend yield of 1.04% and payout ratio of 43.4% provide modest income, but the primary return driver is capital appreciation from multiple expansion and earnings growth. Short-term traders might find opportunities around earnings announcements, but the risk/reward favors a patient, long-term approach.
